You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2025

CLINICAL TRIALS PROFILE FOR MARCAINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Marcaine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00180687 ↗ Clinical Trial of the Use of Intraperitoneal Local Anaesthetic Completed Imperial College London Phase 3 2004-10-01 Patients undergoing keyhole gall bladder removal will be divided into 3 groups, one control, one will have local anaesthetic and the third will have normal saline nebulised into their abdomen before closure of the wounds to reduce postoperative pain. These medications will be given on top of the standard pain management protocol.
NCT00472134 ↗ Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump Completed University Hospitals Cleveland Medical Center N/A 2005-12-01 The purpose of this study is to determine the effects of a local anesthetic dispensed via a tiny catheter device, called the ON-Q PainBuster pump, placed during surgery on top of the mesh used in the laparoscopic repair of ventral hernias. The goals are: - reducing postoperative pain from this procedure - decreasing length of hospital stay - reducing or eliminating amount of post-operative narcotics used
NCT00508066 ↗ Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery Completed Shriners Hospitals for Children Phase 4 2007-05-01 The purpose of this study is to evaluate the effects of continuous local anesthetic delivery on the immediate post-op recovery of patients undergoing spinal fusion surgery for congenital or idiopathic scoliosis.
NCT00508976 ↗ Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic Completed Pinnacle Health System Phase 2 2007-06-01 The purpose of this study is to determine if pre-incisional lidocaine injection, instilled liquid bupivacaine, intra-abdominal aerosolized bupivacaine, or post-operative bupivacaine injection is superior in post-operative pain control in laparoscopic bariatric surgical patients.
NCT00532662 ↗ Postoperative Analgesia by Epidural vs IV Ketamine Concurrent With Caudal Anesthesia in Pediatric Orthopedic Surgery Unknown status Tehran University of Medical Sciences Phase 4 2007-11-01 Preemptive analgesia can improve postoperative pain management. Ketamine may prevent central sensitization during surgery and result in preemptive analgesia. The purpose of this study is to examine the effectiveness of ketamine as a preemptive analgesic as previous studies have shown the involvement of N-methyl-D-Aspartate (NMDA) receptor in neuroplasticity.
NCT00533845 ↗ Intraperitoneal Bupivicaine Infusion Using the On-Q Pain Pump After Laparoscopic Surgery Completed Maimonides Medical Center Phase 4 2007-09-01 After Laparoscopic surgery most patients experience some form of mild to moderate pain. The current standard of care is to treat this pain with local anesthetics (numbing medication, that deadens the nerve endings) to the small surgical incisions (cuts) and narcotic systemic analgesics (medication injected into your vein to control pain such as morphine). Although this treatment improves pain symptoms it is not perfect. Firstly, complete pain control is rarely achieved and secondly, narcotics (such as morphine) often have many side effects including nausea, vomiting, sedation (sleepiness), constipation and abdominal upset. All of these issues make recovery less comfortable and delays return to full function (work, school and other activities of daily life). A new FDA approved device is now available that offers the benefits of long term anesthesia without the side effects of narcotics. It consists of a pump that continuously infuses local anesthesia into and around the surgical site. This pump is placed during your operation. You then carry a tennis ball sized container made of soft plastic in a pouch which drips numbing medicine around your wounds for 2 days continuously. The purpose of this study is to see if this pump improves postoperative pain, decreases the need for narcotic pain medicine and allows people to return to their activities earlier.
NCT00574015 ↗ The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache Completed Albany Medical College Phase 4 2007-12-01 This study will compare the degree of pain control provided by two techniques for persons with toothache in an emergency department. The two techniques include; - standard oral narcotic pain medication - numbing the tooth with local anesthetic by needle injection
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Marcaine Hydrochloride

Condition Name

Condition Name for Marcaine Hydrochloride
Intervention Trials
Pain, Postoperative 38
Pain 26
Postoperative Pain 26
Anesthesia, Local 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Marcaine Hydrochloride
Intervention Trials
Pain, Postoperative 93
Fractures, Bone 9
Hernia, Inguinal 8
Hernia 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Marcaine Hydrochloride

Trials by Country

Trials by Country for Marcaine Hydrochloride
Location Trials
United States 161
Egypt 38
Turkey 19
Canada 17
Israel 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Marcaine Hydrochloride
Location Trials
California 20
New York 17
Illinois 13
Pennsylvania 10
Ohio 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Marcaine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Marcaine Hydrochloride
Clinical Trial Phase Trials
Phase 4 110
Phase 3 24
Phase 2/Phase 3 4
[disabled in preview] 133
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Marcaine Hydrochloride
Clinical Trial Phase Trials
Completed 139
Recruiting 51
Unknown status 32
[disabled in preview] 58
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Marcaine Hydrochloride

Sponsor Name

Sponsor Name for Marcaine Hydrochloride
Sponsor Trials
Istanbul University 12
Cairo University 12
Assiut University 8
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Marcaine Hydrochloride
Sponsor Trials
Other 337
Industry 18
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Marcaine Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction

Marcaine, also known as bupivacaine hydrochloride, is a local anesthetic widely used in various surgical and medical procedures to manage pain. This article provides an update on recent clinical trials, market analysis, and projections for this drug.

Clinical Trials Update

Efficacy of Liposomal Bupivacaine vs Bupivacaine Hydrochloride

A recent multicenter, randomized clinical trial compared the efficacy of liposomal bupivacaine combined with bupivacaine hydrochloride to bupivacaine hydrochloride alone in patients undergoing primary unilateral knee replacement surgery. The study, involving 533 participants, found that liposomal bupivacaine did not improve postoperative recovery or pain compared to bupivacaine hydrochloride alone[1].

Postsurgical Pain Management

Another study, a randomized, double-blind, placebo-controlled trial, evaluated the efficacy of INL-001 (a formulation containing bupivacaine) for postsurgical pain in patients undergoing abdominoplasty. While this study specifically looked at INL-001, it highlights the ongoing research into optimizing bupivacaine formulations for pain management. The study showed improvement in pain intensity and reduced opioid use in the treatment group compared to the placebo group[4].

Market Analysis

Current Market Size

The global market for bupivacaine hydrochloride was estimated to be worth US$ 251 million in 2023. This market is diverse, with several key players including Pfizer, Fresenius Kabi, Hikma Pharmaceuticals, and Baxter, among others[2][5].

Market Projections

The market is forecast to grow to US$ 361.9 million by 2030, with a Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period of 2024-2030. This growth is driven by increasing demand for effective pain management solutions, particularly in regions with high rates of surgical procedures and an aging population[2][5].

Regional Market Dynamics

North America is projected to have the highest CAGR over the forecast period due to its technological advancements in healthcare, high rate of surgical procedures, and a competitive pharmaceutical market. The aging population in this region also contributes to the increased demand for chronic pain management solutions[5].

Key Players and Market Competition

The bupivacaine hydrochloride market is highly competitive, with both generic and brand-name manufacturers. Key players include:

  • Hikma Pharmaceuticals
  • Pfizer Inc.
  • Fresenius Kabi AG
  • Baxter International Inc.
  • AstraZeneca
  • AuroMedics Pharma LLC
  • Shanghai Harvest Pharmaceutical Co.
  • Southwest Pharma
  • Hunan Kelun Pharmaceutical
  • Aurobindo Pharma
  • Sagent Pharmaceuticals[5].

Regulatory and Safety Considerations

Regulatory bodies like the FDA play a crucial role in ensuring the safety and efficacy of bupivacaine hydrochloride formulations. For instance, the FDA has reviewed extensive clinical safety data and pharmacokinetic studies to establish the safety profile of bupivacaine hydrochloride products, such as XARACOLL, which uses a similar mechanism to Marcaine[3].

Technological Advancements and Research Initiatives

The market is driven by continuous research and development initiatives aimed at improving the efficacy and safety of bupivacaine hydrochloride. Innovations such as liposomal formulations and new delivery systems are being explored to enhance the drug's performance and reduce side effects.

Market Trends and Growth Factors

Several factors contribute to the growth of the bupivacaine hydrochloride market:

  • Increasing Surgical Procedures: The rise in elective and non-elective surgeries drives the demand for effective local anesthetics.
  • Aging Population: An aging population increases the incidence of chronic pain conditions, further boosting demand.
  • Technological Advancements: Improvements in drug delivery systems and formulations enhance the market.
  • Competitive Landscape: Strong competition among pharmaceutical companies drives innovation and market growth[5].

Challenges and Limitations

Despite the growth prospects, the market faces challenges such as:

  • Regulatory Hurdles: Strict regulatory requirements can delay market approval for new formulations.
  • Side Effects and Safety Concerns: Bupivacaine hydrochloride, like other local anesthetics, can have side effects, which need to be carefully managed.
  • Generic Competition: The presence of generic alternatives can impact the market share of brand-name products[2][5].

Key Takeaways

  • The global bupivacaine hydrochloride market is expected to grow to US$ 361.9 million by 2030.
  • Recent clinical trials have shown mixed results regarding the efficacy of new formulations.
  • North America is a key region driving market growth due to its high rate of surgical procedures and aging population.
  • The market is highly competitive with several key players.
  • Regulatory and safety considerations are crucial for market approval and consumer trust.

FAQs

What is the current market size of bupivacaine hydrochloride?

The global market for bupivacaine hydrochloride was estimated to be worth US$ 251 million in 2023[2].

What is the projected growth rate of the bupivacaine hydrochloride market?

The market is forecast to grow at a CAGR of 5.4% from 2024 to 2030[2].

Which region is expected to have the highest CAGR for bupivacaine hydrochloride?

North America is projected to have the highest CAGR over the forecast period due to its technological advancements and high rate of surgical procedures[5].

What are the key factors driving the growth of the bupivacaine hydrochloride market?

Key factors include increasing surgical procedures, an aging population, technological advancements, and a competitive pharmaceutical market[5].

Who are the key players in the bupivacaine hydrochloride market?

Key players include Hikma Pharmaceuticals, Pfizer Inc., Fresenius Kabi AG, Baxter International Inc., and several others[5].

Sources

  1. Efficacy of Liposomal Bupivacaine and Bupivacaine Hydrochloride ... - JAMA Surgery
  2. Bupivacaine Hydrochloride - Market Size - Valuates Reports
  3. 209511Orig1s000 - accessdata.fda.gov
  4. A randomized, double-blind, placebo-controlled study to evaluate ... - Regional Anesthesia & Pain Medicine
  5. Bupivacaine Hydrochloride Injection Market CAGR, size, share ... - Strategy Market Research Consulting

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.